ShangBay Capital’s William Dai Named to GrowthCap’s 2022 Top 25 Healthcare Investors List

Rhea-AI Summary

ShangBay Capital, a healthcare-focused venture capital firm, announces that William Dai has been recognized by GrowthCap as one of the top healthcare investors. This recognition highlights his significant contributions to advancing medical technologies. Since founding ShangBay in 2015, Dai has led investments in 55 portfolio companies, achieving multiple successful exits. His previous experience includes serving as CFO for several companies, including ShangPharma (NYSE: SHP) and Nepstar Corporation (NYSE: NPD). Dai emphasizes ShangBay's commitment to supporting entrepreneurs addressing unmet clinical needs.

Positive

• William Dai recognized as a top investor in healthcare by GrowthCap.
• ShangBay Capital invested in 55 portfolio companies since its founding in 2015.
• Successful multiple exits demonstrate effective investment strategy.

Negative

• None.

PALO ALTO, Calif.--(BUSINESS WIRE)-- ShangBay Capital, a venture capital firm focused on investing in healthcare companies, is proud to announce that William Dai has been selected by GrowthCap for his contributions as one of the top investors in healthcare among an impressive list of awardees.

The list recognizes exceptional and talented investors who help advance technologies and innovations to improve patient outcomes and save lives. Awardees were selected based on investment experience and track record, industry impact and advancement, and contributions to portfolio companies’ growth and acceleration.

William Dai, Founding Managing Partner, leads ShangBay’s investment activity in healthcare, focusing on medtech investments. Since the founding of ShangBay Capital in 2015, William has led ShangBay to become a successful VC with 55 portfolio companies to date and multiple exits. William currently serves on the following company boards including SetPoint Medical, Aqua Medical, Emboline, Meditrina, Corinth, FemDx, Apostle, Laplace Interventional, YorLabs, and previously served on the boards of NeuroVasc (acq. in 2019) and Arrinex (acq. by Stryker in 2019).

Previously, William’s work experience spanned more than 20 years in corporate finance, mergers and acquisitions, and capital markets in both Asia and the U.S. Prior to founding ShangBay Capital, he was the CFO of ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK: 00853), and Boston Scientific China. In these roles, William was responsible for the overall execution of business transactions to drive business success.

“ShangBay Capital is committed to backing entrepreneurs that are building solutions for today’s unmet clinical needs. During the pandemic, we’ve seen a tremendous need for disruptive healthcare solutions for people around the world. At ShangBay Capital, it is incredibly rewarding to support and partner with world class founders who are building game-changing medical technologies that help to improve patient outcomes and save lives,” said William Dai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005018/en/

William Dai

williamdai@shangbaycapital.com

Source: ShangBay Capital

FAQ

Who is William Dai and what is his role in ShangBay Capital?

William Dai is the Founding Managing Partner of ShangBay Capital, focusing on healthcare investments.

What companies has William Dai been CFO of?

William Dai served as CFO for ShangPharma (NYSE: SHP) and Nepstar Corporation (NYSE: NPD).

What recognition has William Dai received recently?

William Dai was recognized by GrowthCap as one of the top investors in healthcare.

How many portfolio companies does ShangBay Capital have?

ShangBay Capital currently has 55 portfolio companies.

What is the focus of ShangBay Capital's investments?

ShangBay Capital focuses on investing in healthcare companies, particularly in medtech.